Özet:
Purpose We investigated retrospectively the clinical outcomes of the patients with type iii inflammatory chronic prostatitis, who were treated with fluoroquinolones with and without an α-blocker between 2009-2011. Material and methods Diagnosis was established with medical history (symptoms presented longer than 3 months within previous 6 months), physical examination, Meares-Stamey test and the questionnaire of the NIH-CPSI. The responses to the treatment were assessed with uroflowmetry test and the questionnaire of NIH-CPSI at initial and after 4 weeks of the treatment. The patients with incomplete data and treatment and who treated with α-blockers and/or antibiotics in the period 4 weeks prior to the therapy started in our clinic and had any surgery of lower urinary tract previously were excluded. The patients were classified under 6 groups; group1 = ciprofloxacin, group2 = ofloxacin, group3 = levofloxacin, group4 = ciprofloxacin+tamsulosin, group5 = ofloxacin+tamsulosin, group 6 = levofloxacin+tamsulosin. Wilcoxon Signed Ranks and Kruskal Wallis test were used for comparison of results. Mann Whitney U test with Bonferroni correction made was used as posthoc (P <.05). Results The median scores of NIH-CPSI decreased significantly in all groups (P <.05). Levofloxacin reduced the median total scores of NIH-CPSI more than ciprofloxacin and ofloxacin monotherapies. The combination therapies were better than antibiotic therapies alone and best result was obtained in levofloxacin + tamsulosin combination. Conclusion Tamsulosin + fluoroquinolone (especially tamsulosin + levofloxacin) combinations yielded better results in both NIH-CPSI scores and peak flow rates. © 2012 AEU. Publicado por Elsevier España, S.L. Todos los derechos reservados.